• MeimandSepideh EbrahimiSESchool of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran., Ahmad Pour-Rashidi, ShahrbabakMaryam MasoumiMMDepartment of Obstetrics & Gynecology, Kerman University of Medical Sciences, Kerman, Iran., Esmaeil Mohammadi, MeimandFaridadin EbrahimiFEMinimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran., and Nima Rezaei.
• School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
• World Neurosurg. 2022 Jan 1; 157: e123-e128.

BackgroundGliomas are the most common type of central nervous system tumor in adults, and they have an extremely poor prognosis. Gliomas are classified into 4 grades, with low-grade gliomas (LGGs) constituting grades I and II and glioblastoma multiforme (GBM) constituting grade IV. Breast cancer susceptibility genes BRCA1 and BRCA2 play a role in DNA repair and are required for genome stability.MethodsWe analyzed the LGG and GBM cohorts from The Cancer Genome Atlas. We used Kaplan-Meier and log-rank analysis to determine the relationship between BRCA1 and BRCA2 expression and survival.ResultsCorrelation of BRCA1 and BRCA2 expression with survival in patients with LGG was significant (P = 0.00 and P = 0.00). The higher the levels of expression were, the lower survival rates were in both LGG and GBM cohorts, but the correlation was not significant in patients with GBM (P < 0.01).ConclusionsOur findings suggest that BRCA1 and BRCA2 can be regarded as poor prognostic factors in patients with glioma, with greater significance in patients with LGG. In the future, more in-depth experiments will enable us to elucidate the mechanism of gliomagenesis and identify potential gene therapy targets.Copyright © 2021 Elsevier Inc. All rights reserved.

31 keywords...

hide…